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Prolactin (PRL) secreting tumors are the most common functional neoplasms of the pituitary and are commonly
subdivided into microprolactinomas (<10 mm) and macroprolactinomas (≥10 mm) according to their baseline
diameter. Patients with prolactinoma present with symptoms evolving from hyperprolactinemia and with those
caused by pressure of the expanding mass on surrounding tissues, including the optic chiasm and the cavernous
sinuses. We hereby describe the possible complications of macroprolactinomas, including mass effects,
hypopituitarism, CSF leak and apoplexy and discuss their relevant management.
In general, all patients harboring macroprolactinomas should be treated, the objectives being to achieve normal or
near normal PRL levels, to reduce or stabilize adenoma size and to recover altered pituitary axes. Medical therapy
with dopamine agonists (DA) is the preferred initial treatment for the vast majority of patients harboring
prolactinomas. Pituitary surgery is indicated in patients who cannot tolerate or are resistant to therapy with DAs,
patients that seek fertility and harbor adenomas that impinge on the optic chiasm, psychiatric patients with
contraindication to DA treatment and patients presenting with pituitary apoplexy or a cerebrospinal fluid (CSF) leak.
In addition, in this review, several patient populations with unique clinical characteristics will be discussed
separately namely postmenopausal women, the elderly, children and patients with pituitary carcinoma.
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Prolactin-secreting tumors are the most common func-
tional neoplasms of the pituitary, accounting for 30-40 %
of pituitary adenomas [1]. Prolactinomas are commonly
subdivided into microprolactinomas (<10 mm) and
macroprolactinomas (≥10 mm) according to their baseline
diameter. Patients with prolactinoma can present with
symptoms evolving from hyperprolactinemia which sup-
presses the gonadotroph axis and causes galactorrhea with
amenorrhea or dysmenorrhea in women and erectile dys-
function and decreased libido in men. In addition, patients
might describe symptoms caused by the pressure of the
expanding mass on surrounding tissues, including the
optic chiasm and the cavernous sinuses, resulting in visual
disturbances; or in the compression of the normal pituit-
ary gland, causing hypopituitarism [2, 3].
Several reviews have been published on diagnostic and
therapeutic aspects of prolactinomas [4–8] and there are
clinical guidelines for the management of prolactinomas* Correspondence: ilanshi@clalit.org.il
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creativecommons.org/publicdomain/zero/1.0/[9, 10]. This review will focus on the practical manage-
ment of patients with macroprolactinomas. The treatment
objectives for patients harboring macroprolactinomas are
to achieve normal or near normal prolactin (PRL) levels,
to reduce or stabilize adenoma size and to recover altered
pituitary axes. Below we describe the various methods
used to achieve these goals, the efficacy of the different
therapeutic tools and their possible side effects.
Review
Medical treatment
In general, all patients harboring macroprolactinomas
should be treated. Specific indications include infertility,
tumor mass effects, galactorrhea and hypogonadism [9].
Medical therapy with dopamine agonists (DA) is the pre-
ferred initial treatment for the vast majority of patients
harboring prolactinomas [9–11].
There are several DA agents, including cabergoline
(CAB), bromocriptine (BRC), and quinagolide. However,
the agents in regular use are CAB and BRC [9]. Cabergo-
line is used more often due to several advantages over
BRC. It was shown to achieve higher rates of normopro-
lactinemia and to normalize PRL in BRC resistant patients
[12–14]. Lastly, CAB is administered once or twice weeklyccess article distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in any
ly credited. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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less convenient for most patients and possibly decreasing
their compliance.
Dopamine agonists - PRL response
Since the 1990s CAB was studied as the main thera-
peutic option for hyperprolactinemia in general [15] and
macroprolactinoma in particular [16–29]. The efficacy of
CAB in reducing or normalizing PRL in patients with
macroprolactinomas has been described in many studies
(summarized in Table 1) in which following treatment
with CAB, normal PRL was achieved in 75–95 % of pa-
tients (mean, 79.6 %).
Cabergoline was shown to be superior over other DAs
in several respects, including efficacy. Colao et al. [30]
described a cohort of patients treated with CAB for
macroprolactinomas, either as 1st line, or after treatment
with other DAs. Treatment with CAB achieved normal
PRL levels in 80.8 % (21/26), 51.3 % (19/37) and 94.7 %
(18/19) of patients naïve, resistant or intolerant to other
DAs, respectively. In almost all patients, a reduction of
at least 50 % from baseline PRL level was achieved [9].
In addition to its direct effect on PRL, treatment with
CAB has been effective in improving semen analysis in
men [25] and when used to treat hyperprolactinemic
women with amenorrhea, was found superior to BRC in
gonadal function restoration (72 % vs. 52 %, CAB vs.
BRC, respectively) [15].
Dopamine agonists - adenoma shrinkage
Apart from PRL normalization and hormone secretion re-
covery, tumor shrinkage to relieve tumor mass effects and
prevent neurological complications is another treatmentTable 1 PRL and adenoma size dynamics in patients harboring mac
Author (year) n(M/F) Mean PRL (ng/ml) 1st/current
Ferrari C (1997) [29] 85 (29/56) 300a/NA
Colao A (1997) [22] 23 (8/15) 841/12
Pontikides N (2000) [23] 12 (6/6) 700/7
Colao A (2004) [24] 41 (41/0) 2019/17
De Rosa M (2006) [25] 32 (32/0) 2705/93
Raverot G (2009) [26] 28 (17/11) NA/NA
Ono M (2010) [20] 29 (0/29) 348/6
Bhansali A (2010) [19] 15 (15/0) 6249/47
Karavitaki N (2012) [21] 12 (11/1) 2452/NA
Corsello SM (2003) [17] 10 (10/0) 5794/77
Shimon I (2007) [16] 12 (12/0) 14383/15
Cho EH (2009) [18] 10 (10/0) 11426/109
Total 309 (191/118) 2493/38
aMedian; bCriteria for significant shrinkage varied between studies
Table summarizes publications including ≥10 male subjects, with data on patients wgoal for patients harboring macroprolactinomas [6]. Dopa-
mine agonists decrease the size of macroprolactinomas in
most patients [6, 31, 32]. In a study by Colao et al. [30],
treatment with CAB achieved adenoma disappearance in
61.5 % of patients naïve to DA treatment and an additional
30.8 % demonstrated adenoma shrinkage of >80 %. Pa-
tients intolerant or resistant to other DAs showed lower
adenoma shrinkage rates (42.1 % and 30.3 %, respectively)
[30]. First response to therapy may be expected as soon as
a week or two after treatment initiation. However, in some
patients shrinkage may become noticeable after only
6 months of therapy [31]. Most of the studies (8/11) veri-
fied adenoma shrinkage in response to CAB in all [18–21,
23, 24], or almost all [17, 26] patients, totaling 86.6 % of
treated patients (see Table 1).
Dopamine agonists – resistance
Resistance to DAs has several different definitions in the
literature, including failure to achieve normal PRL levels
or adenoma shrinkage of >50 % [13, 33], failure to re-
duce PRL by >50 %, or to induce ovulation in women
[33], or failure to reduce symptoms or normalize PRL
despite CAB dose ≥2 mg/week [34]. Adenoma shrinkage
is considered an inferior parameter for CAB resistance
due to the limited data in the literature regarding the
correlation with PRL control [13]. The prevalence of
CAB resistance according to this criteria is 11 % among
patients harboring macroprolactinomas [13]. Vroonen
et al. [34], published a study of 92 patients with prolacti-
noma resistance to CAB, including 41 men with macro-
prolactinomas. In this study adenomas resistant to CAB
defined a group of patients with a more advanced dis-
ease and potentially aggressive or even malignantroprolactinoma treated with CAB
PRL normalized n(%) Shrinkageb n(%) Unique study characteristics
52/85 (61.2 %) 41/62 (66.1 %)
19/23 (82.6 %) 14/23 (61 %) Low dose CAB
12/12 (100 %) 12/12 (100 %) CAB as 1st line therapy
31/41 (75.6 %) 41/41 (100 %) Outcome was semen analysis
31/32 (96.8 %) NA Outcome was quality
of seminal fluid
27/28 (96.4 %) 27/28 (96.4 %) Visual field dynamics on CAB
29/29 (100 %) 29/29 (100 %) Outcome was fertility
14/15 (93 %) 15/15 (100 %) Rapid CAB dose escalation
11/12 (91.6 %) 12/12 (100 %) Recovery of hypopituitarism
5/10 (50 %) 9/10 (90 %) Giant prolactinomas
10/12 (83.3 %) 9/11 (81.8 %) Giant prolactinomas
5/10 (50 %) 10/10 (100 %) Invasive giant prolactinomas
246/309 (79.6 %) 219/253 (86.6 %)
ith CAB-treated macroprolactinomas
Tirosh and Shimon Clinical Diabetes and Endocrinology  (2015) 1:5 Page 3 of 8tumors. In the minority of cases, other therapeutic op-
tions such as surgery or external radiation might be con-
sidered, as will be discussed later.
Dopamine agonists – safety and side effects
Rapid shrinkage of prolactinomas may cause pituitary
apoplexy, which is discussed in detail below, see “Com-
plications – Apoplexy”. Moreover, adenoma shrinkage
might cause traction of the optic chiasm and secondary
visual deterioration in patients with chiasmal damage
[26, 35, 36]. Dopamine agonists are used for the treat-
ment of Parkinson’s disease, at a daily dose of at least
2 mg, compared with a typical dose of 0.5–2 mg/week
for macroprolactinomas. Patients treated for Parkin-
son’s are at moderate-to-severe risk for cardiac valvular
damage [10]. However, several studies have shown that
CAB treatment for prolactinomas was not associated
with a clinically significant risk for valvular disease [37,
38]. Hence, the current guidelines do not recommend
routine echocardiography for patients receiving a typ-
ical dose and suggest cardiac-echocardiographic surveil-
lance only for patients treated with very high CAB
doses for prolonged periods [10].
The most common adverse effects of DAs are gastro-
intestinal (nausea, constipation), dizziness (postural
hypotension), headaches and nasal congestion [6].
Other less frequent side effects include fatigue, anxiety,
cold sensitive vasospasm and psychosis. The side effect
profile of CAB is better than BRC [6], making CAB
preferable in routine practice. Leakage of cerebro-
spinal fluid (CSF) following therapy with DA has also
been described [39, 40], especially after rapid shrinkage
of invasive adenomas [41].
Dopamine agonists – treatment duration
The treatment duration with DA for macroprolactino-
mas should be individualized, and depends on the
tumor size and response to the treatment [6]. In one
study [42], withdrawal from therapy according to strict
criteria on follow-up (achieving normal PRL, disappear-
ance or shrinkage of ≥50 % of tumor size, and a 5 mm
distance from the optic chiasm) was associated with re-
currence rate of 36 % 18 months following CAB cessa-
tion and a higher recurrence rate (53.1 %) after a longer
follow-up (24–96 months) period [27]. In line with
these results, guidelines for management of macropro-
lactinomas [9] suggest gradual decrease of CAB dose
after two years of treatment, when PRL is normal and a
shrinkage of ≥50 % is depicted. Among patients with
macroprolactinomas, the presence of both low PRL
levels and adenoma disappearance provided 67 % assur-
ance for permanent or very long-standing remission,
compared with only 22 % assurance for patients with a
visible remnant on MRI [42].Other treatments
Surgery
Medical treatment with DAs is the preferred first-line
treatment for macroprolactinomas [6, 9, 10], as it is
highly effective in most patients (Table 1). However,
there are several indications for pituitary surgery that
might be applicable for a selected group of patients,
specifically those who cannot tolerate, or are resistant
to therapy with DAs, patients that seek fertility and
harbor adenomas that impinge on the optic chiasm,
psychiatric patients with contraindication to DA treat-
ment and patients presenting with pituitary apoplexy
or CSF leak [6]. Cystic prolactinoma is a unique entity,
which usually does not shrink enough under DA treat-
ment and surgery should be considered in invasive
cases [6, 9, 10].
The preferred surgical approach is a trans-
sphenoidal operation, whereas the trans-cranial ap-
proach is reserved for large inaccessible tumors. The
success rates depend on the experience of the neuro-
surgeon [9], but even with experienced surgeons, the
chance for persistent hyperprolactinemia may be high
[43–46]. The expected success rate for normalizing
PRL post-operatively is 65–85 % for microprolactino-
mas but less than 40 % for macroprolactinomas [47].
Furthermore, the long-term cure rate, defined by nor-
mal PRL levels, was only 16 % for macroprolactinomas
[47]. Thus, pituitary surgery for macroprolactinomas
usually results in significant tumor debulking, but
without PRL normalization.Radiotherapy
Radiotherapy is rarely used for PRL-secreting tumors.
Radiotherapy confers several significant adverse effects,
including vascular damage and increased future risk for
stroke, hypopituitarism, damage to the optic chiasm and
secondary brain tumors [9]. Radiotherapy is advised in
cases of DA resistance, malignant prolactinoma and un-
successful surgery [48, 49].
There are several radiotherapy techniques available.
Fractionated stereotactic radiotherapy is saved for
large lesions and requires 25–30 divided doses [50].
By contrast, radiosurgery techniques (e.g., gamma
knife, cyber knife, proton beam) might facilitate the
required radiation delivery in a single dose. Radiosur-
gery achieved biochemical remission in 27 % after
36 months and demonstrated improvement in 54 % of
patients with invasive prolactinomas [51]. In compari-
son, gamma knife radiosurgery achieved a remission rate
in 42 % of patients with Cushing’s disease, 22 months
following radiation [52] and in 50 % of patients with
growth hormone secreting pituitary adenomas after
36 months [53].
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Mass effect
The growing pituitary mass may impinge the surround-
ing structures, depending on the direction and severity
of the extension. Organs that might be harmed include
the optic chiasm, the cranial nerves located in the cav-
ernous sinuses (namely the optic, trochlear, abducens
and two branches of the trigeminal nerves) and other
adjacent structures, such as the temporal lobe, the
nasal cavity and sinuses, the internal ear and the thal-
amus. The related symptoms are mainly headaches and
neuro-ophthalmological, including visual field alter-
ations and ophthalmoplegia. Giant prolactinomas
might also affect remote tissues (see paragraph entitled
“Giant Prolactinomas”).
Visual field defects occur more often in larger aden-
omas [6] and necessitate the evaluation of visual fields in
lesions abutting the optic chiasm [9]. The treatment of
choice for tumors causing visual field defects is DA and
recovery is expected in 75 % of patients, with early ef-
fects a few weeks following treatment initiation [30]. In
our summary of the data of 72 patients with macropro-
lactinomas and visual field defects treated with DAs,
83 % (60/72) improved their vision following medical
treatment (Table 2).
Hypopituitarism
Several studies evaluated the rates of pituitary axes dys-
function in patients harboring macroprolactinomas and
the recovery rates of these deficits following treatment
[30, 35, 54, 55]. The gonadotroph axis is most often dam-
aged (73–86 %), presumably due to the double effect of
the macroprolactinoma on this axis: increased pressure on
the gonadotroph cells from the expanding mass and
suppression of GnRH secretion by PRL effect in the
hypothalamus [7]. Nevertheless, as has been previously
shown [56], normal testosterone levels do not exclude
the presence of PRL-secreting adenoma. Central
hypothyroidism and hypocortisolism might also beTable 2 Effect of medical therapy on visual field defects in patients
Author (year) n(M/F) VFD n(%) V
Ferrari CI (1997) [29] 85 (29/56) 12/85 (14 %) 6
Colao A (1997) [22] 23 (8/15) 10/23 (43 %) 9
Pinzone JJ (2000) [101] 34 (34/0) 14/19 (74 %) 1
Pontikides N (2000) [23] 12 (6/6) 4/12 (33 %) 3
Sibal L (2002) [35] 35 (35/0) 18/35 (51 %) 1
Corsello SM (2003) [17] 10 (10/0) 7/10 (70 %) 6
Shimon I (2007) [16] 12 (12/0) 7/12 (58 %) 7
Total 211 (134/77) 72/196 (37 %) 6
DA Any dopamine agonist, CAB Cabergoline only
aFour patients had secondary visual field deterioration due to optic chiasmal tractioinduced by macroprolactinomas, though less often
(18–41 % and 12–23 %, respectively) [30, 35, 54, 55].
Somatotroph axis evaluation is limited in patients with
PRL-secreting tumors, due to the possibility of GH and
PRL co-secretion in 10 % of these adenomas.
Recovery of the gonadotroph axis was reported in
most patients with macroprolactinomas [21, 30, 54, 55].
The data regarding other pituitary hormones is less con-
sistent. We found some recovery of the corticotrophs
with no thyrotroph recovery [55], Colao et al. [30],
found similar patterns, Karavitaki et al. [21] showed re-
covery of thyrotrophs in 25 % of affected patients but no
recovery of ACTH secretion and Sibal et al. [35] demon-
strated re-secretion of both ACTH and TSH in some pa-
tients in their cohort.
Cerebrospinal fluid leak
A leak in the CSF is usually iatrogenic, due to surgery or
aggressive DA treatment, although it might be the pre-
senting symptom in some macroprolactinomas [17, 19,
57, 58]. In a recent report on this complication of vari-
ous pituitary adenomas [59], PRL-secreting tumors
were reported in 81 % (42/52) of cases, many of these
being giant prolactinomas. Meningitis, a complication
of CSF exposed to the outer environment, was reported
in 15–20 % of cases [60].Apoplexy
Pituitary apoplexy is characterized by a rapid enlargement
of the pituitary due to hemorrhage or infarct [61]. Al-
though this is an uncommon complication, it is potentially
life threatening, characterized by severe and abrupt head-
ache, together with nausea, vertigo and meningismus [62].
Other symptoms might include acute hypopituitarism and
neurologic compromise, including deteriorated conscious-
ness, ophthalmoplegia and restriction of visual fields. Al-
though the syndrome is usually acute and obvious, it may
be subtle or even clinically silent [62].with macroprolactinomas
FD improved n(%) Treatment Unique study characteristics
/12 (50 %) CAB
/10 (90 %) CAB Low dose CAB
1/14 (79 %) DA Primary medical therapy
/4 (75 %) CAB CAB as 1st line therapy
8/18 (100 %)a DA Medical therapy
/7 (86 %) CAB CAB for giant prolactinomas
/7 (100 %) CAB Giant prolactinomas
0/72 (83 %)
n, after primary improvement
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larger lesions, due to increased discrepancy between the
rate of neoplastic progression and blood supply [62].
Lubina et al. [63] reported a group of 40 patients pre-
senting with pituitary apoplexy, of them 63 % harbored
non-secreting adenomas (NFPAs) and 31 % - prolactino-
mas. Semple et al. [61] showed that 77 % of patients
with pituitary apoplexy (48/62) had pathologically con-
firmed NFPAs, while only one had prolactinoma [61].
Importantly, not only treatment with DAs might cause
apoplexy, but also its withdrawal [64], possibly due to
rapid re-growth of the adenoma [65].
The management of pituitary apoplexy depends on
the clinical manifestations and their severity. A main
consequence of apoplexy is the adrenal crisis. Thus, ad-
ministration of hydrocortisone is indicated immediately
on diagnosis, in addition to appropriate glucocorticoid
coverage afterwards. Transsphenoidal surgery for de-
compression of the sella is indicated in patients with
significant visual compromise or with a diminished
level of consciousness [9, 62], whereas conservative
management is optional for others. Furthermore, pa-
tients with apoplexy secondary to prolactinomas, with-
out indications for surgery, were treated with DA with
a good clinical outcome [63].
Special populations
Postmenopausal women
Women usually present with microprolactinomas, in the
age range of 20–40 years, whereas men more frequently
present with macroprolactinomas [66, 67]. Interestingly,
postmenopausal women tend to present with larger and
more invasive tumors compared with premenopausal pa-
tients [68]. The classical explanation for this phenomenon
is the early recognition of hyperprolactinemia due to men-
strual disturbances. However, others have suggested that
the low estrogen milieu might be associated with greater
growth potential [3] and increased mitotic activity [2],
though this notion is still controversial.
Shimon et al. [68] described a group of 14 postmeno-
pausal women with prolactinomas. Thirteen (93 %) har-
bored macroprolactinomas, 4 of them giants (maximal
diameter, 38–50 mm). Among patients treated with CAB,
83 % achieved normal PRL levels, 2–6 months following
treatment initiation. The symptoms of six patients pre-
senting with visual disturbances or diplopia were resolved
following medical treatment. The authors concluded that
despite the large and invasive tumors included in this
unique group, they responded well to DA treatment.
Elderly
Macroprolactinomas might present at any age, though
its prevalence decreases in the elderly [1, 3]. The preva-
lence of macroprolactinomas is higher in men, albeitthey tend to present as macroadenomas both among
older men and women [3, 68, 69]. There are several
challenges in the diagnosis of such patients. First, symp-
toms of hypopituitarism in general and hypogonadism in
particular are less frequent in older patients with prolac-
tinomas [70] and might be mistakenly attributed to
other comorbidities, which are common in this age
group [71]. Second, visual disturbances might also re-
main undetected [70] or masked by other eye patholo-
gies [71], such as cataract. Dopamine agonists are the
mainstay of treatment and are usually effective in the
elderly [70], with a lower incidence of DA resistance
compared to younger patients. Nevertheless, in the se-
lected cases requiring surgery, this latter option is safe in
the elderly, as shown for NFPAs [72, 73].
Children
Prolactinoma is the most prevalent pituitary adenoma in
children, representing half of these patients [74]. Never-
theless, prolactinomas are rare among children, although
other pituitary adenomas in this age group were com-
parable to adults [75]. Most children harboring PRL-
secreting tumors have macroadenomas [74], which
might explain their tendency to develop neurologic com-
plications. The presenting symptoms are usually delayed
puberty and in girls primary amenorrhea and galactor-
rhea [9, 76]. Prolactin-secreting adenomas were reported
in the context of the Familial Isolated Pituitary Adenoma
(FIPA) syndrome linked to AIP gene mutation, although
it is usually associated with acromegaly [77–79]. Screen-
ing for the Multiple Endocrine Neoplasia type 1 (MEN1)
syndrome in the mutations of the menin gene might also
be possible [80]. Salenave et al. [76] found mutations in
AIP and menin in 9 % and 5 %, respectively, in children
with macroprolactinomas. In this cohort, 74 % of pa-
tients (56/76) normalized PRL following DA treatment
and tumor shrinkage was achieved in 76 % (56/74) of
patients, with a median CAB dose of 1.5 mg/week.
Seventeen children in this group required surgery and 2
patients underwent radiotherapy.
Pregnancy
Pregnant women with macroprolactinomas constitute a
unique challenge to the clinician. Diagnostically, PRL
gradually increases throughout pregnancy and cannot be
used for the estimation of tumor size dynamics. Never-
theless, 30 % of macroadenomas grow during pregnancy
[6, 81]. This is attributable to lactotroph hyperplasia in
the estrogen milieu developed during pregnancy. Rou-
tine MRI follow-up during pregnancy is not indicated
for intra-sellar adenomas without clinical signs of tumor
growth [9, 10]. However, severe headache and/or visual
disturbances should prompt formal visual field assess-
ment and MRI, if needed.
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ment for hyperprolactinemia should be avoided during
pregnancy if possible [9, 10]. However, this is difficult to
implement, since pregnancy is usually diagnosed at week
5 (with delayed menstruation), by then the critical
period of organogenesis has already started [82]. The
safety of BRC during pregnancy was confirmed widely
[83, 84], as was for CAB, though to a lesser extent [81,
85–91]. Thus, in case of a large adenoma or symptom-
atic growth during pregnancy, treatment with BRC
should be initiated [10]. In the rare case of a woman
who is planning pregnancy and who has a resistant
macroprolactinoma or has intolerability to DA, pituitary
surgery before pregnancy should be considered [10].Giant prolactinomas
Giant prolactinomas are defined as adenomas larger
than 40 mm [57]. Although these tumors consist only
2–3 % of all prolactinomas, they present some thera-
peutic challenges and unique complications. Giant pro-
lactinomas may invade relatively remote structures and
present with clinical manifestations including epistaxis,
proptosis, nasal obstruction, hydrocephalus, tinnitus,
hearing deficits and temporal epilepsy [48, 57].
A possible pitfall in the diagnosis of giant prolactino-
mas is the “high dose hook effect”. When measuring
PRL levels using a two-site immunometric method, such
as immunoradiometric assay (IRMA) or chemilumines-
cent immunoassay (ICMA), a very high PRL concentra-
tion might saturate the binding sites, causing falsely low
PRL results. The practical solution when evaluating large
pituitary masses, is to repeat the measurement of PRL
levels after dilution of the blood sample [92].
Maiter et al. [57] published a recent review on giant
prolactinomas. Prolactin response to DA (defined as PRL
<25 ng/ml) was achieved in 60 % (58/97) of the patients in
their cohort. Maiter also showed that medical treatment
with DAs achieved significant tumor shrinkage (>50 %) in
most patients, though no reliable pretreatment predictor
for shrinkage was identified [57]. In other reports, DAs
were also very effective in achieving prompt relief of
hydrocephalus caused by giant prolactinomas [93, 94]. It
is important to avoid treatment initiation with high DA
doses, thus to decrease the probability for complications,
such as CSF leak and tumor apoplexy [95].
Surgery is a second line option for the treatment of
giant prolactinomas, as it confers morbidity risks [67]
and usually fails to normalize PRL or to remove the en-
tire tumor [96, 97]. From 97 patients with giant prolacti-
nomas, only 14 required operation [57]. The indications
for surgery were intolerance to DA, CSF rhinorrhea and
resistance to DA with insufficient response or tumor
progression [57].Malignant prolactinomas
Malignant pituitary tumors are rare, with prolactinomas
constituting about third [98]. The initial presentation of
malignant prolactinomas may be identical to benign in-
vasive macroprolactinomas [99]. However, the develop-
ment of DA resistance in a compliant patient or increase
in PRL in discrepancy with stable sellar mass, should
serve as a red alert for malignancy or distant metastases
and prompt further investigation including pituitary bi-
opsy. Metastases of malignant prolactinomas involve
most commonly the central nervous system, but 40 %
may show systemic spread to bones, lymph nodes, lungs
and ovaries [98].
The management of malignant prolactinomas consists
of medical therapy, surgery, radiotherapy and chemo-
therapy. Dopamine agonists should be used in the high-
est tolerable dose to control the hyperprolactinemia [99].
Surgical management should be individualized, and sur-
gical debulking can be performed as palliation, but is
rarely curative [99]. Radiotherapy can be employed in ei-
ther fractionated or radiosurgery techniques, depending
on the spread and location of the lesions (see above
“Other treatments – Radiotherapy”). Temozolomide is
an alkylating agent used for pituitary carcinomas, which
depletes the DNA repairing enzyme o-methyl guanine
DNA methyltransferase (MGMT), but has shown limited
biochemical or tumoral effect in patients with malignant
prolactinomas [100]. The prognosis of PRL-secreting
carcinomas is poor, with only 60 % of patients surviving
more than 1 year [98].
Conclusions
Prolactin-secreting macroadenomas are more common
among men and older patients. Although they com-
monly present as large and invasive tumors, they usually
respond to treatment with DAs and treatment in most
cases is well tolerated. However, there are unique char-
acteristics in different patient populations that might
affect clinical therapeutic decisions and prognosis.
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